Cardior eyes heart failure cure with miRNA inhibitor

Cardior unveiled data on Friday that demonstrates its first clinical candidate goes beyond treating the cardiovascular symptoms of heart failure to reversing established disease in animal models.

Cardior Pharmaceuticals GmbH, which spun out of Hannover Medical School in 2016, is developing non-coding RNA-based therapeutics and diagnostics for cardiovascular diseases. Its lead candidate is CDR132L, a locked nucleic acid (LNA) antisense oligonucleotide against miR-132 for heart failure...